Charles River Laboratories’ first quarter results reflected a mix of ongoing business transformation and operational adjustments. Management pointed to the impact of strategic divestitures, portfolio optimization, and cost-saving measures as key factors shaping performance. CEO Birgit Girshick highlighted that “incremental efficiency initiatives and divestitures” were central to margin improvement efforts, while the company also navigated discrete margin headwinds, including higher costs in its research models and services segment. The quarter was further influenced by stable demand among global pharmaceutical customers, even as small and mid-sized biotech activity varied across regions and segments.
Is now the time to buy CRL? Find out in our full research report (it’s free for active Edge members).
Charles River Laboratories (CRL) Q1 CY2026 Highlights:
- Revenue: $995.8 million vs analyst estimates of $977.4 million (1.2% year-on-year growth, 1.9% beat)
- Adjusted EPS: $2.06 vs analyst estimates of $1.94 (6% beat)
- Adjusted EBITDA: $214.5 million vs analyst estimates of $199.1 million (21.5% margin, 7.7% beat)
- Management slightly raised its full-year Adjusted EPS guidance to $11.05 at the midpoint
- Operating Margin: 12%, up from 7.6% in the same quarter last year
- Organic Revenue fell 1.5% year on year (beat)
- Market Capitalization: $7.84 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Charles River Laboratories’s Q1 Earnings Call
- Elizabeth Anderson (Evercore ISI) asked about seasonal demand trends and the state of new approach methodologies (NAMs); CEO Birgit Girshick explained that seasonality is typical for the business and that NAMs will gradually expand within the core service model through both acquisitions and organic growth.
- Max Smock (William Blair) inquired about the year-over-year and sequential proposal volume growth; Girshick and CFO Glenn Coleman indicated high single-digit growth year-over-year for both pharma and biotech clients, with proposals rising sequentially for three straight quarters.
- Patrick Donnelly (Citi) focused on margin improvement timing and sustainability; Coleman detailed that margin gains in the second half will be driven by portfolio actions and cost initiatives, while Girshick noted continued sluggishness in early-stage biotech demand.
- Kallum Titchmarsh (Morgan Stanley) questioned future M&A and capital allocation priorities; Girshick said ongoing business reviews could lead to further portfolio adjustments, and that the company will continue to pursue both organic investment and selective acquisitions in strategic areas.
- Cassidy Epps (Jefferies) probed the impact of internalizing NHP supply on DSA margins; Coleman responded that margin benefits will materialize as high sourcing costs phase out, with further improvement expected in later quarters.
Catalysts in Upcoming Quarters
In the coming quarters, StockStory analysts will be closely monitoring (1) the pace and impact of margin expansion from recent divestitures and cost-saving initiatives, (2) trends in proposal activity and conversion rates among both large pharmaceutical and biotech clients, and (3) execution of technology and automation rollouts, particularly in digital platforms and AI-driven research tools. Progress in these areas will be essential indicators of Charles River’s ability to deliver on its strategic transformation goals.
Charles River Laboratories currently trades at $162.80, down from $181.73 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).
High-Quality Stocks for All Market Conditions
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum - both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks - FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
